Cyron Therapeutics' CAR-T cell therapy 'CYR-CAR01' has received approval from the Ministry of Food and Drug Safety for Phase 1/2 clinical trials, marking Korea's first CAR-T clinical trial.
CYR-CAR01 is a personalized treatment that extracts patient T-cells, genetically modifies them to recognize and attack cancer cells, then reinfuses them into the patient. It is specifically developed for relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) patients who don't respond to existing treatments.
The company's proprietary technology has reduced CAR-T cell production time from 3-4 weeks to 10 days, and cut manufacturing costs by over 50%. This is expected to provide more patients with timely treatment opportunities.
Clinical trials will be conducted at major domestic medical institutions including Seoul National University Hospital and Samsung Medical Center, and success is expected to open a new chapter in Korea's cell therapy market.